Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | EDNRA | P25101 | 9/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | EDNRB | P24530 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LIMK2 | P53671 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12293612 | 0.85 | MEN1 (0.76) | MEN1CYP3A4KMT2ATSHREDNRA | |
| SCHEMBL12293616 | 0.83 | MEN1 (0.57) | MEN1CYP3A4KMT2ATSHREDNRA | |
| SCHEMBL533130 | 0.83 | PPARG (0.66) | MEN1CYP3A4KMT2ATSHREDNRA | |
| SCHEMBL12293620 | 0.82 | MEN1 (0.59) | MEN1CYP3A4KMT2ATSHREDNRA | |
| SCHEMBL12293607 | 0.82 | MEN1 (0.56) | MEN1CYP3A4KMT2ATSHREDNRA | |
| SCHEMBL533208 | 0.75 | EDNRA (0.62) | EDNRAEDNRB | |
| SCHEMBL27030597 | 0.73 | EDNRA (0.66) | MEN1CYP3A4KMT2ATSHREDNRA | |
| SCHEMBL3917516 | 0.72 | MEN1 (1.00) | MEN1CYP3A4KMT2ATSHREDNRA | |
| SCHEMBL1936832 | 0.72 | MEN1 (0.57) | MEN1CYP3A4KMT2ATSHREDNRA | |
| SCHEMBL7224061 | 0.71 | EDNRA (0.79) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895608-B2 | Sulfonamide anti-viral compounds | Kineta, Inc. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895608-B2 | Sulfonamide anti-viral compounds | Kineta, Inc. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20130039945-A1 | Anti-Viral Compounds | Kineta, Inc. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130039945-A1 | Anti-Viral Compounds | Kineta, Inc. (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2011133729-A2 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130039945-A1 | Anti-Viral Compounds | MAVS, EIF2AK2, IRF3 | MEN1 4873/4885CYP3A4 4242/4885KMT2A 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.